To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus

NCT07619833 ↗

Phase 3 Not yet recruiting 510 enrolled Daewoong Pharmaceutical Co. LTD.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aims to evaluate the efficacy and safety of initial combination therapy with DWP16001 and DWC202518 compared to DWP16001 monotherapy and DWC202518 monotherapy in patients with Type 2 Diabetes Mellitus

Timeline

Start: 2026-06
Primary completion: 2027-11
Completion: 2027-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DWC202518	Unknown	—	Oral
Subject	Enavogliflozin	Small molecule	0.3 mg	Oral

To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus

Summary

Timeline

Drugs

Indications